Adrenocortical tumors associated with the TP53 p.R337H germline mutation can be identified during child‐care consultations

Abstract

ObjectiveTo evaluate the clinical features associated with adrenocortical hormone overexpression and familial cancer profiling as potential markers for early detection of adrenocortical tumors in children from South and Southeast Brazil. MethodsThe clinical manifestations and anthropometric measurements of 103 children diagnosed with adrenocortical tumors were analyzed. ResultsBetween 1982 and 2011, 69 girls and 34 boys diagnosed with adrenocortical tumors were followed‐up for a median time of 9.0 years (0–34 years). Signs of androgen overproduction alone (n=75) or associated with cortisol (n=18) were present in 90.3%. TP53 p.R337H mutation was found in 90.5% of patients. Stages I, II, III, and IV were observed in 45.6%, 27.2%, 19.4%, and 7.8% of patients, respectively. At diagnosis, there were no significant differences in height (p=0.92) and weight (p=0.22) among children with adrenocortical tumors, but children with virilization alone had significantly higher height‐for‐age Z‐scores (0.92±1.4) than children with hypercortisolism alone or combined (−0.32±1,8; p=0.03). The five‐year overall survival was 76.7% (SD±4.2). Patients with advanced‐stage disease had a significantly worse prognosis than those with limited disease (p<0.001). During follow‐up, ten of 55 p.R337H carrier parents developed cancer, whereas none of the 55 non‐carriers did. ConclusionsSigns of adrenocortical hormone overproduction appear early, even in cases with early‐stage. These signs can be identified at the physical examination and anthropometric measurements. In southern Brazil, pediatric adrenocortical tumor is a sentinel cancer for detecting families with germline p.R337H mutation in TP53 gene.